INmune Bio Inc.
INMBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeINmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. Valued at $52.4M, INMB is a micro-cap name in its sector. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Market Cap
$52.4M
Beta
0.98
P/E (TTM)
—
P/E (Fwd)
-3.75
EPS (TTM)
$-1.61
EPS (Fwd)
$-0.53
ROE
-168.8%
ROA
-52.6%
Cash
$21.4M
Total Debt
$1.5M
Free CF
-$11.2M
52W Change
-17.9%
Annual Financials
Cash vs Debt
Where INMB stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, INMB finished 36.49% above its 150-day moving average ($1.48) and 29.49% above its 200-day moving average ($1.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INMB overbought or oversold?
At the July 15, 2026 close, INMB's RSI(14) was 76.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $21.4M in cash and $1.5M in debt, INMB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$11.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -168.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $374K (2022) to $50K (2025), a 87% decline worth watching.
With cash comfortably exceeding debt, INMB has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence INmune Bio Inc.'s trajectory.